Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Life Sciences
Hdac6 Inhibitors Sensitize Non-Mesenchymal Triple-Negative Breast Cancer Cells To Cysteine Deprivation, Tahiyat Alothaim, Morgan Charbonneau, Xiaohu Tang
Hdac6 Inhibitors Sensitize Non-Mesenchymal Triple-Negative Breast Cancer Cells To Cysteine Deprivation, Tahiyat Alothaim, Morgan Charbonneau, Xiaohu Tang
Michigan Tech Publications
Triple-negative breast cancer (TNBC) is a highly malignant type of breast cancer and lacks effective therapy. Targeting cysteine-dependence is an emerging strategy to treat the mesenchymal TNBC. However, many TNBC cells are non-mesenchymal and unresponsive to cysteine deprivation. To overcome such resistance, three selective HDAC6 inhibitors (Tubacin, CAY10603, and Tubastatin A), identified by epigenetic compound library screening, can synergize with cysteine deprivation to induce cell death in the non-mesenchymal TNBC. Despite the efficacy of HDAC6 inhibitor, knockout of HDAC6 did not mimic the synthetic lethality induced by its inhibitors, indicating that HDAC6 is not the actual target of HDAC6 inhibitor …